| Species |
Varicella-zoster virus (strain Oka vaccine) |
| Protein Construction |
Envelope glycoprotein E (Ser31-Tyr538)
Accession # Q9J3M8 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1 EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
58.39 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 65-85 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
VZV glycoprotein E (gE) is most abundantly expressed on the surface of infected cells, and is an essential component for virus replication and cell-to-cell transmission. It is also the main target of virus-specific antibodies and T cell responses that is often selected as vaccine candidate antigen. |
| Synonyms |
Envelope glycoprotein E; gE; ORF68; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
